You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 15, 2025

Drug Price Trends for MERZEE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for MERZEE

Average Pharmacy Cost for MERZEE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
MERZEE 1 MG-20 MCG CAPSULE 43386-0371-32 0.79458 EACH 2025-01-22
MERZEE 1 MG-20 MCG CAPSULE 43386-0371-32 0.73663 EACH 2024-12-18
MERZEE 1 MG-20 MCG CAPSULE 43386-0371-32 0.67570 EACH 2024-11-20
MERZEE 1 MG-20 MCG CAPSULE 43386-0371-32 0.82126 EACH 2024-10-23
MERZEE 1 MG-20 MCG CAPSULE 43386-0371-32 0.88327 EACH 2024-09-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Market Analysis and Price Projections for Merzee

Introduction

Merzee, a generic equivalent of the oral contraceptive Taytulla, was launched by Slayback Pharma in 2021. This analysis will delve into the market dynamics, competitive landscape, and price projections for Merzee, providing insights into its position within the pharmaceutical market.

Market Context

The pharmaceutical market, particularly for generic drugs, is highly competitive and influenced by various factors including regulatory changes, market demand, and the presence of other generic and branded competitors.

Competitive Landscape

Merzee, as a generic version of Taytulla, enters a market where multiple oral contraceptives are already available. The launch of Merzee triggered a 180-day period of Competitive Generic Therapy (CGT) exclusivity, which does not restrict the continued commercialization of other generics of Taytulla but provides Slayback Pharma a temporary market advantage[4].

Market Trends and Growth

Generic Drug Market

The generic drug market is growing due to increasing demand for affordable healthcare options. Generic drugs, including oral contraceptives like Merzee, benefit from this trend as they offer cost-effective alternatives to branded medications.

Regulatory Environment

Recent regulatory changes, such as those introduced by the Inflation Reduction Act, aim to lower prescription drug costs. While these changes primarily target branded drugs, they also influence the broader pharmaceutical market, including generics. For instance, the act's provisions to negotiate lower prices for certain drugs under Medicare can indirectly affect the pricing strategies of generic drug manufacturers[5].

Price Projections

Current Pricing

As a generic drug, Merzee is priced lower than its branded counterpart. However, specific pricing details for Merzee are not publicly available. Generally, generic drugs are significantly cheaper than their branded equivalents, making them more accessible to a wider audience.

Future Pricing Trends

  • Inflation and Market Dynamics: The overall pharmaceutical market is expected to experience a moderate level of price inflation. For example, Vizient projects a 3.81% drug price inflation rate for 2025, which could influence the pricing of generic drugs as well[2].
  • Competition: As the CGT exclusivity period for Merzee ends, the market will become more competitive. This could lead to price adjustments to maintain market share.
  • Regulatory Impact: While the Inflation Reduction Act primarily targets branded drugs, the overall push for lower drug prices could lead to a more price-sensitive market, potentially affecting the pricing of generics.

Market Size and Growth Potential

Oral Contraceptive Market

The market for oral contraceptives is stable, with a consistent demand driven by the need for reproductive health services. The launch of Merzee expands the options available to consumers, potentially capturing a share of this market.

Generic Drug Market Growth

The generic drug market is expected to continue growing due to the increasing demand for affordable medications. This trend is likely to benefit Merzee and other generic oral contraceptives.

Key Takeaways

  • Competitive Advantage: Merzee's initial 180-day CGT exclusivity provided a temporary market advantage.
  • Pricing Strategy: Merzee is priced lower than its branded counterpart, aligning with the general trend for generic drugs.
  • Market Trends: The pharmaceutical market is subject to inflation and regulatory changes, which can influence pricing.
  • Growth Potential: The stable demand for oral contraceptives and the growing generic drug market present opportunities for Merzee.

FAQs

  1. What is Merzee used for? Merzee is an oral estrogen/progestin combination oral contraceptive used by women to prevent pregnancy[4].

  2. Who launched Merzee? Merzee was launched by Slayback Pharma LLC in 2021[4].

  3. What is the significance of the 180-day CGT exclusivity for Merzee? The 180-day CGT exclusivity period triggered by Merzee's launch does not restrict the continued commercialization of other generics of Taytulla but provides Slayback Pharma a temporary market advantage[4].

  4. How does the Inflation Reduction Act impact the pricing of generic drugs like Merzee? While the act primarily targets branded drugs, the overall push for lower drug prices could lead to a more price-sensitive market, potentially affecting the pricing of generics[5].

  5. What are the projected price trends for the pharmaceutical market in 2025? The pharmaceutical market is expected to experience a 3.81% price inflation rate in 2025, according to Vizient's projections[2].

Sources

  1. Competition in Prescription Drug Markets, 2017-2022 - ASPE
  2. Vizient projects drug price inflation at 3.81% - Vizient Inc.
  3. Alzheimer's Drugs Global Market Overview 2024 - Business Wire
  4. Slayback Pharma announces launch of Merzee - PR Newswire
  5. FACT SHEET: Biden-Harris Administration Announces New, Lower Prices for First Ten Drugs Selected for Medicare Price Negotiation - The White House

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.